CDIAG Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Chidamide, Decitabine Combined With Priming IAG Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

This study is to investigate the therapeutic efficacy and side effect of chidamide, decitabine combined with priming IAG regimen for relapsed or refractroy acute myeloid leukemia

Inclusion Criteria:

• Relapsed or refractory acute myeloid leukemia patients without severe complications such as active infections and bleedings; ECOG score less than 3.

Exclusion Criteria:

• Inablity to tolerate inducton chemotherapy; life expectancy less than 1 month